BiotechTube

mifepristone + placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psychotic Depression

Conditions

Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis

Trial Timeline

Mar 1, 2008 → Jun 1, 2014

NCT ID
NCT00637494

About mifepristone + placebo

mifepristone + placebo is a phase 3 stage product being developed by Corcept Therapeutics for Psychotic Depression. The current trial status is terminated. This product is registered under clinical trial identifier NCT00637494. Target conditions include Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT05217758Phase 2Completed
NCT00637494Phase 3Terminated
NCT00146523Phase 3Completed

Competing Products

14 competing products in Psychotic Depression

See all competitors
ProductCompanyStageHype Score
Olanzapine, Amantadine + Olanzapine and placeboEli LillyPhase 1
33
risperidone IR and LAI formulationJohnson & JohnsonPhase 1
33
quetiapineAstraZenecaPhase 3
77
QuetiapineAstraZenecaPhase 3
77
QuetiapineAstraZenecaPhase 3
77
quetiapine + olanzapine + risperidoneAstraZenecaPre-clinical
23
Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved
85
Ziprasidone HCL (oral)PfizerApproved
84
AripiprazoleBristol Myers SquibbPhase 3
76
Aripiprazole + Risperidone/QuetiapineBristol Myers SquibbPre-clinical
22
Miricorlilant + Miricorlilant + PlaceboCorcept TherapeuticsPhase 2
47
Miricorilant + FluvoxamineCorcept TherapeuticsPhase 1
28
Miricorilant + PlaceboCorcept TherapeuticsPhase 2
47
Olanzapine + CORT118335 + PlaceboCorcept TherapeuticsPhase 1
28

Other Products from Corcept Therapeutics

Mifepristone 300 MG [Korlym] + Placebo for mifepristoneApproved
80
mifepristonePhase 3
72
RelacorilantPhase 3
72
Mifepristone + placeboPhase 3
72
RelacorilantPhase 3
72